Abstract 【Objective】To investigate the correlation between plasma microRNA-21 (miR-21) ,peripheral blood mononuclear cell helper T cell subsets 17 (Th17) cells and regulatory T cells (Treg) in patients with ulcerative colitis. 【Methods】 A total of 102 patients with ulcerative colitis (observation group) admitted to our hospital from August 2017 to December 2019 were selected,and 114 healthy volunteers (control group) who underwent physical examination in our hospital at the same time were selected. The levels of miR-21 in plasma were detected by real-time fluorescent quantitative PCR (qRT-PCR),Th17 cells and Treg cells were detected by flow cytometry,and the levels of interleukin-17 (IL-17) and transforming growth factor-β(TGF-β) in plasma were detected by enzyme-linked immunosorbent assay (ELISA),levels of interleukin-10 (IL-10) and interleukin-21 (IL-21); the correlation between plasma inflammatory factor levels and miR-21,Th17/Treg levels in patients with ulcerative colitis,and the factors affecting the occurrence of ulcerative coliti were analyzed. 【Results】 The levels of miR-21,Th17 cells and Th17/Treg in the observation group were higher than those in the control group,and the levels of Treg cells were lower than those in the control group (P<0.05). The levels of IL-17 and IL-21 in the observation group were higher than those in the control group,The level of TGF-β and IL-10 was significantly lower than that of the control group (P<0.05). Pearson analysis showed that the levels of miR-21 and Th17/Treg in patients with ulcerative colitis were positively correlated (r=0.598,P<0.05),and the levels of miR-21 and Th17/Treg were positively correlated with the levels of IL-17 and IL-21,and was negatively correlated with the level of TGF-β and IL-10 (P<0.05). Logistic regression analysis showed that miR-21 and Th17/Treg were independent risk factors for ulcerative colitis (P<0.05). TGF-β was the protective factor of ulcerative colitis (P<0.05). 【Conclusion】 Patients with ulcerative colitis have a serious imbalance of Th17/Treg,and the imbalance of Th17/Treg may be closely related to the level of miR-21.
ZHANG Yi,JIU Meng-na. Expression of miR-21 in Peripheral Blood of Patients with Ulcerative Colitis and its Correlation with Th17/Treg Balance[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(6): 889-892.
[1] FUJITA K,MIZUMOTO Y,MORIYOSHI K,et al. Acute onset of ulcerative colitis during chemoradiotherapy for anaplastic lymphoma kinase-positive lung adenocarcinoma:Ulcerative colitis during chemoradiotherapy[J].Respirol Case Rep,2018,6(2):1-3.
[2] 李红,刘震雄,窦维佳. 溃疡性结肠炎患者miR-21和miR-206的表达及临床意义[J].医学综述,2019,25(15):3085-3089.
[3] FU Z W,ZHANG Z Y,GE H Y. Mesenteric injection of adipose-derived mesenchymal stem cells relieves experimentally-induced colitis in rats by regulating Th17/Treg cell balance[J].Am J Transl Res,2018,10(1):54-66.
[4] 种靖慧,解金辉. Th17细胞及其分泌的IL-17在自身免疫性疾病中的作用[J].继续医学教育,2018,32(7):129-131.
[5] 孙广超,曾华松. 活动期全身型幼年特发性关节炎患儿外周血Th17/Treg的变化及意义[J].山东医药,2019,59(25):27-30.
[6] 胡品津,钱家鸣,吴开春,等. 我国炎症性肠病诊断与治疗的共识意见(2012年?广州)[J].内科理论与实践,2013,8(1):61-75.
[7] 季芳,高文艳,鞠宝兆. 基于“络病”理论谈溃疡性结肠炎的病机特征及意义[J].辽宁中医杂志,2019,46(7):1406-1411.
[8] PEKOW J,MECKEL K,DOUGHERTY U,et al. Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitis[J].Oncotarget,2018,9(29):20709-20720.
[9] LI M G,LIU X Y,LIU Z Q,et al. Bcl2L12 contributes to Th2-biased inflammation in the intestinal mucosa by regulating CD4+ T cell activities[J].J Immunol,2018,201(2):725-733.
[10] 胡伟,王森,王贤,等. 系统性红斑狼疮患者外周血Th1/Th2/Th17/Treg的表达水平及其临床意义[J].东南大学学报:医学版,2019,38(2):308-312.
[11] 陈孝国,王荣芋,施培华. Th17、Treg细胞及其相关细胞因子对溃疡性结肠炎发病的影响[J].皖南医学院学报,2018,37(4):325-327.
[12] LIU Q,YANG W,LUO Y,et al. Correlation between miR-21 and miR-145 and the incidence and prognosis of colorectal cancer[J].J BUON,2018,23(1):29-35.
[13] THORLACIUS-USSING G,SCHNACK-NIELSEN B,ANDERSEN V,et al. Expression and localization of miR-21 and miR-126 in mucosal tissue from patients with inflammatory bowel disease[J].Inflamm Bowel Dis,2017,23(5):739-752.
2022, Vol. 39 
